Want to see IN:KOPRAN full AI Analyst Report?
KOPRAN Stock Chart & Stats
₹152.20
-₹3.64(-1.71%)
At close: 4:00 PM EST
₹152.20
-₹3.64(-1.71%)
Day’s Range― - ―
52-Week Range₹107.00 - ₹242.80
Previous CloseN/A
Volume53.95K
Average Volume (3M)14.35K
Market Cap
₹11.20B
Enterprise Value₹6.66K
Total Cash (Recent Filing)₹6.82M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)45.0
Beta1.42
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.29%
Share Statistics
EPS (TTM)5.17
Shares Outstanding48,285,606
10 Day Avg. Volume22,270
30 Day Avg. Volume14,348
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.98
Price to Sales (P/S)0.77
P/FCF Ratio-49.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthThe FY2026 acceleration indicates stronger recent demand across the business. Sustained top-line expansion can improve operating scale and support investment in pharmaceutical products, APIs, and distribution capabilities over the coming quarters.
Conservative LeverageModerate leverage gives Kopran a relatively solid financial base and reduces balance-sheet pressure compared with highly indebted peers. The substantial equity cushion should help the company fund operations and absorb earnings volatility.
Diversified Pharmaceutical OperationsOperating across APIs and finished dosages provides exposure to both B2B pharmaceutical supply and branded or generic medicine distribution. Multiple therapeutic areas and domestic and international channels can reduce dependence on one product or market.
Bears Say
Persistent Negative Free Cash FlowRepeatedly negative free cash flow indicates that investment needs or working-capital demands are absorbing internally generated funds. If sustained, this can limit financial flexibility and increase reliance on external funding for growth.
Volatile ProfitabilityUneven margins and the FY2026 decline in net income weaken earnings visibility despite revenue growth. Persistent profitability volatility could constrain reinvestment, reduce the benefits of operating scale, and make future performance less predictable.
Rising Total DebtA rising debt balance adds financial obligations while cash generation remains weak. Even with moderate leverage today, continued borrowing could reduce flexibility and increase refinancing or interest-burden risks if profitability or free cash flow does not improve.
Kopran Limited News
KOPRAN FAQ
What was Kopran Limited’s price range in the past 12 months?
Kopran Limited lowest stock price was ₹107.00 and its highest was ₹242.80 in the past 12 months.
What is Kopran Limited’s market cap?
Kopran Limited’s market cap is ₹11.20B.
When is Kopran Limited’s upcoming earnings report date?
Kopran Limited’s upcoming earnings report date is Nov 05, 2026 which is in 60 days.
How were Kopran Limited’s earnings last quarter?
Kopran Limited released its earnings results on Aug 07, 2026. The company reported ₹1.388 earnings per share for the quarter.
Is Kopran Limited overvalued?
According to Wall Street analysts Kopran Limited’s price is currently Overvalued.
Does Kopran Limited pay dividends?
Kopran Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of 1.29%. See more information on Kopran Limited dividends here
What is Kopran Limited’s EPS estimate?
Kopran Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kopran Limited have?
Kopran Limited has 48,285,606 shares outstanding.
What happened to Kopran Limited’s price movement after its last earnings report?
Kopran Limited reported an EPS of ₹1.388 in its last earnings report. Following the earnings report the stock price went down -4.727%.
Which hedge fund is a major shareholder of Kopran Limited?
Currently, no hedge funds are holding shares in IN:KOPRAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kopran Limited
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a diverse array of dosage formats, such as tablets, capsules, dry powders, suspensions, and injectable solutions. The company's active pharmaceutical ingredients cater to a broad spectrum of therapeutic applications, encompassing macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, antihistamines, anti-acne treatments, anti-infectives, urologicals, anti-thrombotics, antidiabetics, pain management, gastroenterology, and cardiovascular medications. Established in 1958, Kopran Limited maintains its corporate headquarters in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Sanofi India Limited
―
SMS Pharmaceuticals Limited
―